- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
- Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
- Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
- Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Veracyte Completes Acquisition of C2i Genomics
More ▼
Key statistics
On Friday, Veracyte Inc (VCYT:NMQ) closed at 19.31, 3.76% above its 52-week low of 18.61, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.55 |
---|---|
High | 19.77 |
Low | 19.16 |
Bid | 18.97 |
Offer | 19.67 |
Previous close | 19.48 |
Average volume | 734.65k |
---|---|
Shares outstanding | 78.44m |
Free float | 77.54m |
P/E (TTM) | -- |
Market cap | 1.53bn USD |
EPS (TTM) | -1.02 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼